A Phase II/III, multicenter, partially randomized, open label trial investigating safety and efficacy of ondemand and prophylactic treatment with BAY 94-9027 in severe hemophilia A
|Effective start/end date
|4/24/12 → 12/31/18
- BAYER HEALTHCARE PHARMACEUTICALS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.